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1. Introduction 
Over the last three decades hot-melt extrusion (HME) has emerged as an  influential 
processing technology in developing molecular dispersions of active pharmaceutical 
ingredients (APIs) into polymers matrices and has already been demonstrated to provide 
time controlled, modified, extended and targeted drug delivery resulting in improved 
bioavailability [1, 2, 3, 4]. HME has now provided opportunity for use of materials in order 
to mask the bitter taste of active substances. Since industrial application of the extrusion 
process back in the 1930’s HME has received considerable attention from both the 
pharmaceutical industry and academia in a range of applications for pharmaceutical dosage 
forms, such as tablets, capsules, films and implants for drug delivery through oral, 
transdermal and transmucosal routes [5]. This makes HME an excellent alternative to other 
conventionally available techniques such as roll spinning and spray drying. In addition to 
being a proven manufacturing process, HME meets the goal of the US Food and Drug 
Administration's (FDA) process analytical technology (PAT) scheme for designing, 
analyzing as well as controlling the manufacturing process through quality control 
measurements during active extrusion process [6]. In this chapter we review the hot-melt 
extrusion technique, based on a holistic perspective of its various components, processing 
technologies as well as the materials and novel formulation design and developments to its 
varied applications in oral drug delivery systems. 
2. Hot-melt extrusion (HME): Process technology 
Joseph Brama first invented the extrusion process for the manufacturing of lead pipes at the 
end of the eighteenth century [7]. Since then, it has been used in the plastic, rubber and food 
manufacturing industries to produce items ranging from pipes to sheets and bags. With the 
 Recent Advances in Novel Drug Carrier Systems 4 
advent of high throughput screening, currently more than half of all plastic products 
including bags, sheets, and pipes are manufactured my HME and therefore various 
polymers have been used to melt and form different shapes for a variety of industrial and 
domestic applications. The  technology (HME) has proven to be a robust method of 
producing numerous drug delivery systems and therefore it has been found to be useful in 
the pharmaceutical industry as well [8]. Extrusion is the process of pumping raw materials 
at elevated controlled temperature and pressure through a heated barrel into a product of 
uniform shape and density [9]. Breitenbach first introduced the development of melt 
extrusion process in pharmaceutical manufacturing operations [10], however, Follonier and 
his co-workers first examined the hot melt technology to manufacture sustained release 
polymer based pellets of various freely soluble drugs [11]. HME involves the compaction 
and conversion of blends from a powder or a granular mix into a product of uniform shape 
[9]. During this process, polymers are melted and formed into products of different shapes 
and sizes such as plastic bags, sheets, and pipes by forcing polymeric components and 
active substances including any additives or plasticisers through an orifice or die under 
controlled temperature, pressure, feeding rate and screw speed [9, 12]. However, the 
theoretical approach to understanding the melt extrusion process could be summarized by 
classifying the whole procedure of HME compaction into the followings [13]:  
1. Feeding of the extruder through a hopper 
2. Mixing, grinding, reducing the particle size, venting and kneading 
3. Flow through the die. 
4. Extrusion from the die and further down-stream processing. 
 
 
Figure 1. Schematic diagram of HME process [12]. 
The extruder generally consists of one or two rotating screws (either co-rotating or counter 
rotating) inside a stationary cylindrical barrel. The barrel is often manufactured in sections 
in order to shorten the residence time of molten materials. The sectioned parts of the barrel 
are then bolted or clamped together. An end-plate die is connected to the end of the barrel 
which is determined according to the shape of the extruded materials. 
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3. Equipment: Single screw and twin screw extruder 
A single screw extruder consists of one rotating screw positioned inside a stationary barrel 
at the most fundamental level. In the more advanced twin-screw systems, extrusion of 
materials is performed by either a co-rotating or counter-rotating screw configuration [9]. 
Irrespective of type and complexity of the function and process, the extruder must be 
capable of rotating the screw at a selected predetermined speed while compensating for the 
torque and shear generated from both the material being extruded and the screws being 
used. However, regardless of the size and type of the screw inside the stationary barrel a 
typical extrusion set up consists of- a motor which acts as a drive unit, an extrusion barrel, a 
rotating screw and an extrusion die [13]. A central electronic control unit is connected to the 
extrusion unit in order to control the process parameters such as screw speed, temperature 
and therefore pressure [14]. This electronic control unit acts as a monitoring device as well. 
The typical length diameter ratios (L/D) of screws positioned inside the stationary barrel are 
another important characteristic to consider whether the extrusion equipment is a single 
screw or twin screw extruder. The L/D of the screw either in a single screw extruder or a 
twin screw extruder typically ranges from 20 to 40:1(mm). In case of the application of pilot 
plant extruders the diameters of the screws significantly ranges from 18-30 mm.  In 
pharmaceutical scale up, the production machines are much larger with diameters typically 
exceeding 50-60mm [15]. In addition, the dimensions of a screw change over the length of 
the barrel. In the most advanced processing equipment for extrusion, the screws could be 
separated by clamps or be extended in proportion to the length of the barrel itself. A basic 
single screw extruder consists of three discrete zones: feed zone, compression and a 
metering zone (Fig. 2). Under the compression zone which is basically know as processing 
zone could be accompanied by few other steps such as mixing, kneading, venting etc [13, 
15]. 
 
Figure 2. Schematic diagram of a single screw extruder [10]. 
The depth along with the pitch of the screw flights (both perpendicular and axial) differ 
within each zone, generating dissimilar pressures along the screw length (Fig. 3). Normally 
the pressure within the feed zone is very low in order to allow for consistent feeding from 
the hopper and gentle mixing of API, polymers and other excipients and therefore the screw 
flight depth and pitch are kept larger than that of other zones. At this stage of the process 
the pressure within the extruder is very low which subsequently gets increased in the 
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compression zone. This results in a gradual increase in pressure along the length of the 
compression zone which effectively imparts a high degree of mixing and compression to the 
material by decreasing the screw pitch and/or the flight depth [9, 15]. Moreover the major aim 
of the compression zone is not only to homogenize but also compress the extrudate to 
ensure the molten material reaches the final section of the barrel (metering zone) in a form 
appropriate for processing. Finally the final section which is known as the metering zone 
stabilizes the effervescent flow of the matrix and ensures the extruded product has a 
uniform thickness, shape and size. A constant and steady uniform screw flight depth and 
pitch helps maintain continuous high pressure ensuring a uniform delivery rate of 
extrudates through the extrusion die and hence a uniform extruded product. 
 
Figure 3. Screw geometry (extrusion) [9]. 
In addition to the above mentioned systems, downstream auxiliary equipment for cooling, 
cutting, collecting the finished product is also typically employed. Mass flow feeders to 
accurately meter materials into the feed hopper, pelletizers, spheronizer, roller/calendaring 
device in order to produce continuous films and process analytical technology such as near 
infra-red (NIR) and Raman, ultra sound, DSC systems are also options. Throughout the 
whole process, the temperature in all zones are normally controlled by electrical heating 
bands and monitored by thermocouples.  
The single screw extrusion system is simple and offers lots of advantages but still does not 
acquire the mixing capability of a twin-screw machine and therefore is not the preferred 
approach for the production of most pharmaceutical formulations. Moreover, a twin-screw 
extruder offers much greater versatility (process manipulation and optimisation) in 
accommodating a wider range of pharmaceutical formulations making this set-up much 
more constructive. The rotation of the screws inside the extruder barrel may either be co-
rotating (same direction) or counter-rotating (opposite direction), both directions being 
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equivalent from a processing perspective. A greater degree of conveying and much shorter 
residence times are achievable with an intermeshing set-up. Furthermore, the use of reverse-
conveying and forward-conveying elements, kneading blocks and other intricate designs as 
a means of improving or controlling the level of mixing required can help the configuration 
of the screws themselves to be varied [16].  
 
Figure 4. A twin screw extruder and screws [9]. 
4. Advantages of HME  
HME offers several advantages over conventionally available pharmaceutical processing 
techniques including: (a) increased solubility and bioavailability of water insoluble 
compounds, (b) solvent free non ambient process, (c) economical process with reduced 
production time, fewer processing steps, and a continuous operation, (d) capabilities of 
sustained, modified and targeted release, (e) better content uniformity in extrudates, (f) no 
requirements on the compressibility of active ingredients, (g) uniform dispersion of fine 
particles,  (h) good stability at changing pH and moisture levels and safe application in 
humans, (i) reduced number of unit operations and production of a wide range of 
performance dosage forms, and (j) a range of screw geometries [17, 18, 19, 20, 21]. 
However, HME has some disadvantages as well. The main drawbacks of HME include: 
thermal process (drug/polymer stability), limited polymers, high flow properties of 
polymers and excipients required and not suitable for relatively high heat sensitive 
molecules such as microbial species, proteins etc [20, 21]. 
5. Applications of HME  
Extrusion technology is one of the most important fabrication processes in the plastic and 
rubber industries. Products made from melt extruded polymers range from pipes to hoses 
through to the insulated wires, cables, rubber sheeting and polystyrene tiles. Plastics that are 
commonly processed by HME technique include acrylics and cellulosics, polyethylene, poly 
propylene, polystyrene and vinyl plastics [9, 22].  In the food industry, extrusion has been 
utilized for pasta production with a widely used multitalented technique combines cooking 
and extrusion in a self-styled extrusion cooker [23].  In the animal feed industry and 
veterinary science, extrusion is commonly applied as a means of producing pelletized feeds, 
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implants or injection moulding [24]. HME has successfully been applied in the formulation 
of fast dispersing PVP melt extrudates of poorly soluble active agents as solid molecular 
dispersions in the crop protection field [25]. 
HME technology has already achieved a strong place in the pharmaceutical industry and 
academia due to several advantages over traditional processing methods such as roll 
spinning, grinding [18]. In addition to being an efficient manufacturing process, HME 
enhances the quality and efficacy of manufactured products and therefore over the past few 
years HME has emerged as a novel technique in the pharmaceutical applications [15, 28]. 
The main use of HME is to disperse active pharmaceutical ingredients (APIs) in a matrix at 
the molecular level, thus forming solid solutions [26]. In the pharmaceutical industry, HME 
has been used for various applications, such as i) enhancing the dissolution rate and 
bioavailability of poorly soluble drug by forming a solid dispersion or solid solution, ii) 
controlling or modifying the release of the drug, iii) taste masking of bitter APIs, and iv) 
formulation of various thin films [27]. 
The bioavailability of an active ingredient is controlled by its aqueous solubility. Therefore 
increasing the solubility of water insoluble drugs is still a real challenge in the formulation 
development process [26]. Due to the advent of high throughput screening (HTS) in the 
drug discovery process, the resultant compounds are often high molecular weight and 
highly lipophilic and therefore exhibit poor solubility [29]. Scientists have already tried to 
address solubility issues by various pharmaceutical interventions. Among the many 
methods available to improve solubility and dissolution rate, preparation of solid 
dispersions and solid solutions has gained vast attention. For that reason HME has been 
successfully applied to prepare solid molecular dispersion of APIs into different hydrophilic 
polymer matrices [26, 29]. 
6. Formulation research and developments to dates 
Despite the fact that initial research developments have focused on the effects of 
formulation and processing variables on the properties of the final dosage forms, [9, 30, 31, 
34, 35] more recent investigations have focused on the use of HME as a novel manufacturing 
technology of solid molecular dispersions through to the development of mini-matrices, 
taste masked formulations and also sustained release formulations as well as paediatric 
formulations [26, 48]. Early work by De Brabander et al. (2000) described the preparation of 
matrix mini-tablets which was followed by further investigations into the properties of 
sustained release mini-matrices manufactured from ethyl cellulose, HPMC and ibuprofen 
[32, 33]. Extruded mini tablets showed minimised risk of dose dumping, reduced inter- and 
intra-subject variability. Very recently, Roblegg et al. (2011) reported the development of 
retarded release pellets using vegetable calcium stearate (CaSt) as a thermoplastic excipient 
processed through HME, where pellets with a drug loading of 20% paracetamol released 
only 11.54% of the drug after 8 hours due to the significant densification of the pellets. As 
expected, the drug release was influenced by the pellet size and the drug loading [36]. A 
microbicide intravaginal ring (IVRs) IVR was prepared and developed from polyether 
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urethane (PU) elastomers for the sustained delivery of UC781 (a highly potent 
nonnucleoside reverse transcriptase inhibitor of HIV-1). PU IVRs containing UC781 were 
fabricated using a hot-melt extrusion process [37]. 
Moreover, a fourfold increase in the availability of propanolol in the systemic circulation 
was observed when the HME formulation was compared with a commercially available 
formulation (Inderal®). Over the last five years HME has been used largely to manufacture 
granules, pellets, immediate and modified release tablets, transmucosal/ transdermal films 
and implantable reservoir devices [3, 4, 9,35]. For instance, with respect to drug 
administration through the oral route, molecular solid dispersions of nifedipine [38], 
nimodipine [29] and itraconazole [39, 40,41] have been successfully produced using HME 
technology. Amorphous indomethacin dispersions have been manufactured using 
pharmaceutically acceptable hydrophilic polymers by using HME technology [26, 42,43].  
Furthermore, HME research developments have driven targeted drug delivery systems 
including enteric matrix tablets and capsule systems over the last few years [44, 45]. Miller et 
al. (2007) have demonstrated the ability of HME to act as an efficient dispersive process for 
aggregated, fine engineering particles to improve dissolution rate properties by enhancing 
particles’ wettability [46]. A very interesting investigation of Verreck and co-workers (2006) 
[47] determined the use of supercritical carbon dioxide (scCO2) as a temporary plasticiser 
during the manufacture of ethylcellulose through HME. A significant reduction in the 
processing temperature was achieved using scCO2 without any disadvantageous effects on 
the extrudate. Macroscopic morphology was significantly altered due to expansion of the 
scCO2 in the die. The use of scCO2 increased the surface area, porosity and hygroscopicity 
of the final dosage forms. More recently Douroumis and co-workers used HME technique to 
effectively enhance the solubility of ibuprofen, indomethacin and famotidine [26, 42]. 
The taste masking of bitter APIs is a major challenge especially for the development of 
orally disintegrating tablets (ODT). HME has been reported to be an effective technique to 
mask the bitter tastes of various APIs by the use of taste masking polymers that create solid 
dispersions to prevent bitter drugs from coming in contact with the patient’s taste buds.  
Breitkruitz et al. (2008) successfully applied HME in taste masking of sodium benzoate for 
the formulation of paediatric drugs [48]. More recently Grycze et al. (2011) and 
Maniruzzaman et al. (2012) developed taste masked formulations of ibuprofen and 
paracetamol, respectively [26, 48]. Basically taste masking is achieved through 
intermolecular forces (e.g. hydrogen bonding) between the active substance and the 
polymer matrix by processing oppositely charged compounds through HME [49, 50]. The 
extrusion of solid lipids using twin–screw extruders was introduced for the preparation of 
immediate or sustained release taste masked matrices [51]. In this process, occasionally 
called “solvent – free cold extrusion” the lipids are extruded below their melting ranges. 
Consequently, the lipids are not melted during extrusion and build a coherent matrix with 
low porosity. In these few studies the effect of lipid composition and processing parameters 
such as the die diameter, the size of the extruded pellets, the screw speed and the powder 
feeding rates on the obtained drug release patterns were thoroughly investigated. Very 
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recently, Breitkreutz et al. (2012) applied solid lipid extrusion at room temperature for the 
taste masked formulation development of the BCS Class II drug NXP 1210. In this study, the 
authors investigated powdered hard fat (Witocan® 42/44 mikrofein), glycerol distearate 
(Precirol® ato 5) and glycerol trimyristate (Dynasan® 114) as lipid binders. The lipid based 
formulations design in this study was feasible for taste-masked granules or pellets 
containing poorly soluble drugs [52]. 
6.1. Films by hot-melt extrusion  
Only a handful of researchers have reported the use of hot-melt extrusion for the 
manufacture of films. Films can be defined as thin sheets containing one or more polymers 
with or without a plasticiser and may be used as a drug delivery system (device) or directly 
applied to facilitate a therapeutic effect as in wound dressings. Films are currently being 
produced mainly by solvent casting in which polymers (and excipients such as plasticisers) 
are dissolved in a suitable solvent until they form clear viscous solution (gel). While film 
preparation using the solvent–casting approach allows film uniformity, clarity, flexibility 
and adjustable thickness to accommodate drug loadings they are limited by decreased 
elongation or elasticity and increased film tensile strength when physical aging is applied 
[53]. Another, limitation associated with solvent cast films is the use of organic solvents for 
water insoluble polymers. The hazardous nature of most organic solvents and the residual 
solvents after drying affect the selection of the appropriate solvent [54–57] as well as 
complicated processing conditions and disposal of the associated waste, all of which create 
significant environmental concerns. As a result, alternative technologies are needed in the 
pharmaceutical industry to overcome some of challenges described above. The two commonly 
used approaches include spray coating and hot melt extrusion with the latter becoming 
increasingly popular due to the many advantages it provides. Firstly, no solvents are used and 
fewer processing steps are required. In fact one of the key advantages of HME is the fact that 
extrudates can be obtained in a single processing step making it very economical. As far as 
films are concerned, there is no requirement for compressing of the active ingredients together 
with the excipients. The melting of the polymer into the molten state, coupled with the 
thorough initial mixing allows a more uniform dispersion of fine particles. Further, molecular 
dispersion of the drug helps improve its bioavailability [58].  Hot melt extruded films are 
produced through a simple process involving blending of appropriate amounts relevant 
polymer, drug and plasticiser into a uniform powdered mixture prior to feeding through the 
hopper of the preheated extruder and transferred into the heated barrel by a rotating extruder 
screw. Homogeneous films are obtained with thickness generally expected to be in the range 
less than 1mm. Generally three main ingredients are required for successful formulation of hot 
melt films i.e. film forming polymer, active ingredient and plasticiser [59]. The latter is 
required to impart flexibility to the final film which ensures ease of handling and application 
to the site of action. Occasionally, other additives are added to affect other functionally 
important properties such as bioadhesive agent which ensures that the film adheres to the 
mucosal surface for a long enough time to allow drug absorption or action. Different polymers 
and drugs have been employed and reported in the literature for obtaining drug loaded hot-
melt extruded films for various indications and are summarised in table 1.  
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Film Main polymer(s) Plasticiser/additive Main active 
ingredient(s) 
Autho
r 
1 Acrylic 
Eudragit 
- Triacetin 
- Triethylcitrate 
Lidocaine [60] 
2 Hydroxypropylcellulose 
Polyethylene oxide 
N/A Ketoconazole [61] 
3 Hydroxypropylcellulose 
Hydroxypropylmethylce
llulose 
Polyethylene oxide 
Polyethylene glycol 
3350 
Lidocaine [62] 
4 Hydroxypropylcellulose Polyethylene glycol 
400 
Hydrocortisone [65] 
5 Hydroxypropylcellulose 
Polycarbophil 
Polyethylene glycol 
3350 
Clotrimazole [58] 
6 Polyethylene oxide N/A Ketoprofen [59] 
Table 1. Different hot-melt extruded films comprising different polymeric materials, plasticisers and 
active ingredients for various indications.  
Repka and co-workers have conducted extensive research on the use of HME for the 
manufacture of mucoadhesive buccal films. They successfully evaluated different matrix 
formers and additives for the processing of the blend prior to extrusion [61, 62, 63, 64]. In an 
early investigation, it was found that even though films containing exclusively HPC could 
not be obtained, the addition of plasticizers, such as triethyl citrate, PEG 2000/8000, or 
acetyltributyl citrate, allowed for the manufacture of thin, flexible, and stable HPC films [65]. 
It has also been found that increasing the molecular weight of HPC decreased the release of 
drugs from hot-melt extruded films which resulted in dissolution profiles exhibiting zero-
order drug release. According to the models applied in the research, the drug release was 
solely determined by erosion of the buccal film [66, 67, 68]. 
Development of films by HME may present future opportunities to develop gastro-retentive 
films for prolonged drug delivery and multi-layer films to modulate drug release for oral 
and transdermal applications. The growing market in medical devices, including 
incorporating drugs such as biodegradable stents and drug-loaded catheters will 
undoubtedly require HME manufacturing processes. These are required to be 
commercialised and perhaps may lead to new areas of collaboration across pharmaceutical, 
medical device and biotechnology research. 
7. HME in commercial products 
HME related patents which have been issued for pharmaceutical systems have steadily 
increased since the early 1980’s.  So far, the USA and Germany hold approximately more 
than half (56%) of all issued patents for HME in the market [69]. Despite this increased 
interest, only a handful of commercialized HME pharmaceutical products are currently 
 Recent Advances in Novel Drug Carrier Systems 12 
marketed. Several companies have been recognized to specialize in the use of HME as a 
drug delivery technology, such as PharmaForm and SOLIQS (Abbott). Recently, SOLIQS 
has developed a proprietary formulation which is known as Meltrex® and re-developed a 
protease-inhibitor combination product, Kaletra®. Kaletra is mainly used for the treatment 
of human immunodeficiency virus (HIV) infections. The formulated, melt extruded product 
was shown to have a significant enhancement in the bioavailability of active substances [70]. 
Furthermore, HME Kaletra® tablets were shown to have significant advantages for patient 
compliance (i.e. reduced dosing frequency and improved stability) compared to the 
previous soft-gel capsule formulation as recognized by the FDA decision to fast-track 
approval. Additionally, Nurofen (Meltlets® lemon) is available on the market as a fast 
dissolving tablet prepared by HME [42]. Ibuprofen has been used as active substance in the 
Meltlets® tablets where its bitter taste was successfully masked by similar technique to 
HME. Moreover, SOLIQS has also developed a fast-onset ibuprofen system and a sustained-
release formulation of verapamil (Isoptin® SR-E) through a HME related technology called 
‘Calendaring’ that was the first directly shaped HME product on the market.  
8. Summary 
HME has proven to be a robust method of producing numerous drug delivery systems and 
therefore it has been found to be useful in the pharmaceutical industry enlarging the scope 
to include a range of polymers and APIs that can be processed with or without plasticizers. 
It has also been documented that HME is a solvent-free, robust, quick and economy 
favoured manufacturing process for the production of a large variety of pharmaceutical 
dosage forms. 
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